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COLLABORATIVE STUDY OF BLADE ATRIAL SEPTOSTOMY 
Sang C. Park MD, FACC; William H. Neches MD, FACC; 
Charles E. Mullins MD, FACC; Robert A. Mathews MD; 
Frederick J. Fricker MD; Lee B. Beerman MD, Cora C. 
Lenox MD, FACC. J. R. Zuberbuhler MD, FACC 
University of Pittsburgh School of Medicine andchildren's 
Hospital of Pittsburgh, Pittsburgh, Pa. 
During the past 3 years, 5 institutions have colla- 
borated in an evaluation of the efficacy of blade atria1 
septostomy (BS). Forty-three patients underwent BS, 
including 25 with transposition of the great arteries 
(TGA), 10 with mitral atresia complex (MAC), 3 with tri- 
cuspid atresia (TAT) and 5 with miscellaneous anomalies. 
Ages ranged from 1 day to 12 years. 'Twenty-nine (67X) 
were under 6 months of age, 6 between 7 and 12 months 
and 8 were older than 1 year at the time of BS. 
Clinical improvement occurred in 20 of 25 (80%) patients 
with TGA. In 2 patients a large atria1 septal defect 
(ASD) was created by the procedure but adequate mixing 
did not occur and early Mustard operation was performed. 
Three other patients had borderline size ASD prior to BS 
and the blade did not engage the interatrial septum (IAS). 
Seven of 10 patients with MAC had a good result with BS. 
In 2 patients in this group the IA was too small to per- 
mit extension of the blade. Three patients with TAT and 
the 5 patients in the miscellaneous group had an excel- 
lent result. Immediate improvement occurred in 81% of 
the 43 cases. Four patients had intact IAS and.BS was 
successfully performed by transseptal technique. Among 
17 patients who have undergone follow-up evaluation of 
interatrial opening (IAO) re-stenosis of the IAS was 
observed in 3 patients 10 to 22 months after the BS. 
There was a single mortality, a result of laceration of 
the left atria1 wall. Minor complications were observed 
in 3 patients. BS is an effective palliative procedure, 
even with thickened IAS or with an intact IAS. 
HEMODYNAMIC EFFECTS OF HYDRALAZINE IN INFANTS WITH 
LARGE VENTRICULAR SEPTAL DEFECT. 
Robert H. Beckman, M.D., Albert P. Rocchini, M.D., Amnon 
Rosenthal, M.D., F.A.C.C., University of Michigan Medical 
School, C.S. Mott Children's Hospital, Ann Arbor. 
To evaluate the effects of acute afterload reduction, 
Hydralazine (HZ, .2 mg/kg) was administered at cardiac 
catheterization to 6 infants with large ventricular 
septal defect (VSD). Age ranged from 2.5 to 11 (mean 
5.3) months. Prior to HZ and 5, 15, 25, and 35 minutes 
after HZ the following were measured: Ao, pulmonary 
capillary wedge (PcW), PA, RA, SVC pressures and saturat- 
ions, heart rate (HR), and oxygen consumption (V02). 
Hemodynamic effects were noted 5 minutes post-HZ but 
were most pronounced 35 minutes post-HZ. Pre-HZ baseline 
data were therefore compared to 35 minute post-HZ values. 
Pulmonary flow (Qp) did not change while systemic flow 
(Qs) in5reased significantly (4.6 If 0.3 to 6.6 + 0.5 
L/min/m' , pc.01, mean + SEM). The Qp/Qs ratio decreased 
(3.5 + 0.4 to 2.3 + 0.3, pc.01) as did the absotute left 
to right shunt (11.1 t 1.5 to 8.2 + 1.4 L/min/m , 
pc.05). As expected HZ caused a significant decrease in 
systemic resistance (Rs, 13.5 + 0.7 tc 9.6 + 0.8 units, 
pc.001). Pulmonary resistance, PcW pressures, HR, and 
V02 did not change following HZ. A small but significant 
decrease in RA pressure (4.2 t 0.7 to 2.3 + 0.7 mmHg, 
pc.05) was observed. In conclusion, HZ caused a signifi- 
cant increase in Qs, and a significant decrease in both 
Qp/Qs ratio and absolute left to right shunt in 6 
infants with large VSD. These effects appear to be 
related to the decrease in Rs which occurred with HZ. 
This is in contrast to our previous work documenting 
hemodynamic deterioration with nitroprusside in a 
similar group of infants with VSD. Thus, HZ may be 
beneficial in the management of infants with large VSD. 
SAFETY AND EFFICACY OF SHORT AND LONG TERM VERAPAMIL 
THERAPY IN CHILDREN WITH TACHYCARDIA 
David Sauire. MD; Nargo Schleman, MD; Anna O'Riordan, MD; 
Iain Black, MD, Temple University and St. Christopher's 
Hospital for Children, Philadelphia, PA and The Univer- 
sity of Texas Medical Branch, Galveston, Texas 
Seven children aged 3 months to 11 years have been treated 
with Verapamil (V) because of resistant, symptomatic su- 
praventricular tachycardia (SVT), or because of compli- 
cations of conventional therapy. Two of 3 patients with 
congenital heart disease were post-operative. The others 
had no gross cardiac anomalies. Three patients had SVT 
with WPW syndrome, 3 had ectopic SVT and 1 had atria1 
flutter (AF). Intravenous V was given in a dose of 0.15 
to 0.25 mg/kg in 6 patients, 4 of whom converted success- 
fully. One patient was placed on oral V only. Treatment 
failed in the patient with AF and one patient with WPW 
and a wide QRS tachycardia. Five patients were placed on 
continuing oral therapy. One patient died of post-oper- 
ative complications while on V. Four patients have re- 
mained on oral V for 1 to 4 years at this time. The dose 
is 80 mg., 6 or 8 hourly depending upon response. Two of 
these have ectopic SVT which recurs when therapy is stop- 
ped. In the 2 with WPW and SVT, one patient has had no 
recurrences and in the other attacks have decreased from 
l-2/week to l-2/month. The duration of these attacks has 
also diminished. There have been no side effects of 
chronic drug administration. None of the 6 patients who 
received intravenous V showed any untoward effects during 
administration. Our experience indicates that V which so 
far has not been used extensively in children is an effec- 
tive and safe anti-arrhythmic drug capable of controlling 
both ectopic and re-entrant SVT when conventional methods 
fail. The presence of underlying congenital heart disease 
should not be contraindication to its use. 
CLINICAL AND ELECTROPHYSIOLOGIC PREDICTION OF NEED FOR 
PACEMAKER INSERTION IN CHILDREN WITH CONGENITAL COMPLETE 
ATRIOVENTRICULAR BLOCK 
Peter P. Karpawich, MD; Paul C. Gillette, MD, FACC 
The Lrllre Frank Abercrombie Section of Pediatric 
Cardiology, Baylor College of Medicine, Houston 
The criteria for pacemaker insertion (PM) in patients with 
congenital complete AV block (CCAVB) have not been defined 
In an attempt to define such criteria we evaluated 22 
children with CCAVB, ages 1 day-14y (median 7y) with sur- 
face ECG, treadmill exercise testing (TM) noting change in 
resting heart rate (HR) and prevalence of ventricular 
ecto y (PVC) and intracardiac electrophysiologic studies 
(EPSP including identification of site of block corrected 
pacemaker recovery time (CPRT), and His to vent;icle 
interval (HV). Patients were followed 1-19~ (median 6y) 
noting age of onset of any syncopal episodes (SX). Associ- 
ated congenital heart defects (CHD) were found in 5/22 
children. Site of block was localized to the AV node (AVN) 
in 17/22, His Bundle (HB) in 3/22, below HB (BHB) in l/22, 
aqd was unknown in 1 22 patients. 
INo.lBLOCK StiHNCHDI SXI 
Data aye as follows: 
EPS I TM 
SX patients revealed AVN block in 617, 3 of whom had SX at 
2v of ape. The HR in all SX natients was <52BPM whereas 
nb patient with HR>52BPM experienced syncope (p<O.Ol). 
CPRT estimation was performed in 4/7 SX patients; all were 
>200omsec. However, 3 asymptomatic patients also had 
CPRT>2OOOmsec. The XAin HR during TM was not signifi- 
cantly different between sites of block. We conclude: 
1. Localization of CCAVB to the AVN does not mitigate 
against syncope; 2. The best single predictor of SX either 
clinically or during EPS was a low HR; 3. EPS may be of 
little benefit as neither site of block nor CPRT are valid 
predictors of SX; 4. TM is of little benefit in predicting 
site of block or SX. 
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